LauraJKlesseMD

Pediatric Hematology & Oncology • Dallas, TX

Cancer Genetics/Cancer Risk Assessment, Pediatric Neuro-Oncology

Associate Professor, Pediatrics, University of Texas Southwestern Medical Center, Southwestern Medical School

Join to view full profile

Dr. Klesse is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Klesse's full profile

Already have an account?

Office
5323 Harry Hines Blvd
Stop 9063
Dallas, TX 75390
Phone+1 214-528-2050

Fax+1 214-648-3122

Summary

Dr. Laura Klesse is a pediatric hematologist/oncologist in Dallas, TX and is affiliated with multiple hospitals in the area, including Children's Medical Center Dallas, University of Texas Southwestern Medical Center, and Children's Medical Center Plano. She received her medical degree from University of Texas Southwestern Medical School and has been in practice 16 years. She specializes in cancer genetics/cancer risk assessment and pediatric neuro-oncology.

Education & Training

University of Texas Southwestern Medical CenterFellowship, Pediatric Hematology/Oncology, 2005 - 2008
University of Texas Southwestern Medical CenterResidency, Pediatrics, 2002 - 2005
University of Texas Southwestern Medical SchoolClass of 2001

Certifications & Licensure

TX State Medical License 2007 - 2026
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Everolimus for Children With Recurrent or Progressive Ependymoma Start of enrollment: 2015 Feb 01
Completed
Phase 2
Evaluation of [18F]FLT PET/CT as an Early Predictor of Outcome in Pediatric Solid Tumors Start of enrollment: 2019 Aug 13
Withdrawn
Early Phase 1
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Start of enrollment: 2019 Sep 29
Active, not recruiting
Phase 2
Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas Start of enrollment: 2024 Dec 15
Not yet recruiting
Phase 2
Roles: Contact
Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas Start of enrollment: 2022 Jun 20
Recruiting
Phase 2, Phase 3
Roles: Contact
Frameshift Peptides of Children With NF1 Start of enrollment: 2019 Apr 11
Completed
Roles: Contact, Principal Investigator
A Phase II Trial of Poly-ICLC for Low-Grade Gliomas Start of enrollment: 2021 Dec 15
Recruiting
Phase 2
Roles: Contact
The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study Start of enrollment: 2015 Oct 01
Active, not recruiting
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform Neurofibroma.
Christopher L Moertel, Angela C Hirbe, Hans H Shuhaiber, Kevin Bielamowicz, Alpa Sidhu
Journal of Clinical Oncology. 2024-11-08
14 citations
A critical assessment of using ChatGPT for extracting structured data from clinical notes.
Jingwei Huang, Donghan M Yang, Ruichen Rong, Kuroush Nezafati, Colin Treager
NPJ Digital Medicine. 2024-05-01
1 citations
Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1.
Andrea M Gross, Scott R Plotkin, Nelson B Watts, Michael J Fisher, Laura J Klesse
Clinical Trials. 2024-02-01

Press Mentions

Family of Three-Year-Old Cancer Patient Wears Superhero Costumes to Every ChemoMay 3rd, 2022
ChatGPT Can Extract Data from Clinical NotesMay 9th, 2024

Professional Memberships

American Society of Clinical Oncology - ASCO
Member